Strategic Advancements and Market Opportunities Propel Verastem's Buy Rating
Verastem Oncology Completes Rolling NDA Submission To The FDA For Avutometinib Plus Defactinib As A Treatment For Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer; Seeking Accelerated Approval And Priority Review Of Its NDA Submission In Patients...
Express News | Verastem Inc - FDA Filing Decision Expected Before End of 2024 With Potential for FDA Approval Decision by Mid-2025
Express News | Verastem Oncology Completes Rolling Nda Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent Kras Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology to Participate in Upcoming Investor Conferences
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
